logo
Marathon popularity leaves runners susceptible to scammers

Marathon popularity leaves runners susceptible to scammers

When Jess Iapella went to buy a resale ticket to the sold-out Gold Coast half marathon she thought she was internet savvy enough to avoid being fleeced by a scammer.
Ms Iapella, a 36-year-old executive assistant on the Gold Coast, put out a call for a ticket on a marathon Facebook page that had 4,000 members.
She received numerous offers and decided to buy from someone who appeared to be a genuine runner, with a profile picture of them wearing a race medal.
Ms Iapella agreed to transfer half the money via PayID, but it soon became apparent there was no ticket.
The popularity of the Gold Coast marathon has grown exponentially in recent years.
Tickets for this year's half marathon, which cost up to $170, sold out in four hours, while the full marathon, priced at up to $215, sold out in four days.
More than 10,000 people are on the waiting list, leaving many desperate to take part.
David Tuffley, a cybersecurity expert from Griffith University, said scammers were looking to capitalise on people's fear of missing out.
"There's been an upsurge in this kind of thing around the world, any major sporting event seems to attract this, where thousands of people are coming in," Dr Tuffley said.
Like most scams, Dr Tuffley said there were red flags to look out for.
"If the offer is well below what you would expect, that's the number one point. The second point is if there's a sense of urgency — and there is always a sense of urgency involved in these scams — they get people," he said.
Dr Tuffley said people used to be able to spot scams by bad spelling or poor English, but now with the rise of AI helping scammers write copy, scams were harder to detect.
Gold Coast Marathon organisers said they had worked to scam-proof the event, with the transfer of tickets done exclusively through the registration portal.
While the marathon did not offer an official resale platform, Gold Coast Marathon CEO Ben Mannion said runners could transfer tickets and when done correctly through the portal no money changes hands between individuals.
"We want to control the opportunity that people buy legitimate entries," he said.
"Just like any event, whether it's a Taylor Swift concert or anything involving ticketing, you're going get scammers.
"We want people to be diligent and be smart with what they do so it's really easy to contact us and we can talk them through the transfer process."
Jess Iapella said when she reported the fake profile to Meta it was quickly taken down, but she thinks the tech giant should be doing more to protect users.
"Couldn't they detect the profile earlier rather than later if they have knowledge that this Facebook profile is not legit and there are pictures taken from another runner?" she said.
As for the marathon, she intended to try to run again next year — even though she would approach the event with less trust.
"I'm definitely disappointed, but I'm definitely going to be watching it and maybe next year I'll be ready to run the full marathon," she said.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Lunch Wrap: ASX loses fizz as soft CPI lifts banks; DroneShield soars on record deal
Lunch Wrap: ASX loses fizz as soft CPI lifts banks; DroneShield soars on record deal

News.com.au

time42 minutes ago

  • News.com.au

Lunch Wrap: ASX loses fizz as soft CPI lifts banks; DroneShield soars on record deal

ASX fizzles as soft CPI lifts banks, hammers miners DroneShield rockets on record European order Paladin names new CEO The ASX bolted out of the blocks on Wednesday, up nearly half a per cent inside the first hour, but the early fizz went flat by lunch. Local traders digested a mixed brew of softer inflation and wobbly commodity prices. Overnight in New York, the bulls were on parade. The S&P 500 added 1.1% and the tech-heavy Nasdaq almost clinched a fresh record, up 1.5%. Fed boss Jerome Powell told Congress there's 'no rush' to slice rates, but conceded cuts will come 'sooner rather than later' if inflation behaves. Oil prices kept sliding, and WTI has now dropped almost 15% in two sessions to hover near US$65 a barrel. Much of that retreat hangs on Donald Trump's hastily brokered ceasefire between Israel and Iran, complete with his trademark all-caps warnings: 'DO NOT DROP THOSE BOMBS'. Back home, the inflation reading landed this morning, with May CPI easing to 2.1% year-on-year, better than the 2.3% the punters tipped and well below April's 2.4%. The trimmed mean – the RBA's pet measure – slipped to 2.4% from 2.8%, still inside the holy-grail 2–3 per cent band which is good. Back to the ASX, where bank stocks led. Commonwealth Bank (ASX:CBA) hit another record $192 before paring gains. Miners copped the heaviest selling after iron-ore futures dipped again in Singapore. Fortescue (ASX:FMG) slid 2%. The gold crew also lost their shine as haven demand cooled. Northern Star Resources (ASX:NST) dropped a hefty 2.7%. In the large caps front, it was anything but dull. Defence tech darling DroneShield (ASX:DRO) stole the headlines, rocketing 22% after sealing its biggest single contract yet – a $61.6 million order from a European military customer for handheld counter-drone gear. Among the other movers, freshly relisted Virgin Australia (ASX:VGN) climbed another 3.5% after finishing 10% higher on debut yesterday. Xero (ASX:XRO) is in a trading halt pending its potential US$2.5 billion acquisition of New York fintech, Melio. And, uranium miner Paladin Energy (ASX:PDN) named chief operating officer Paul Hemburrow as its new CEO from 1 September. ASX SMALL CAP WINNERS Here are the best performing ASX small cap stocks for June 25 : Security Description Last % Volume MktCap OVT Ovanti Limited 0.007 133% 239,057,184 $9,016,545 RLC Reedy Lagoon Corp. 0.002 100% 5,130,468 $776,707 LIS Lisenergylimited 0.135 45% 3,714,033 $59,538,621 CDE Codeifai Limited 0.064 33% 4,604,031 $21,261,046 HCD Hydrocarbon Dynamics 0.002 33% 1,816,797 $1,617,164 MGU Magnum Mining & Exp 0.004 33% 172,779 $3,364,953 AN1 Anagenics Limited 0.005 25% 105,000 $1,985,281 ERA Energy Resources 0.003 25% 85,665 $810,792,482 FBM Future Battery 0.020 25% 268,651 $10,770,576 OMG OMG Group Limited 0.005 25% 1,721,869 $2,913,180 TEG Triangle Energy Ltd 0.003 25% 1,050,660 $4,178,468 SUM Summitminerals 0.038 23% 855,713 $2,745,858 DRO Droneshield Limited 2.170 22% 23,021,475 $1,561,051,854 AON Apollo Minerals Ltd 0.006 20% 140,000 $4,642,284 FRX Flexiroam Limited 0.006 20% 200,019 $7,586,993 OLI Oliver'S Real Food 0.006 20% 2,846,964 $2,703,660 PWN Parkway Corp Ltd 0.012 20% 8,434,707 $27,671,139 PPK PPK Group Limited 0.340 17% 242,989 $26,335,624 BMG BMG Resources Ltd 0.007 17% 100,000 $5,066,383 WBE Whitebark Energy 0.004 17% 551,397 $2,062,001 RPG Raptis Group Limited 0.043 16% 67,311 $12,975,340 CHW Chilwaminerals 1.220 16% 58,992 $56,907,194 MCA Murray Cod Aust Ltd 1.185 15% 29,820 $108,947,776 NME Nex Metals Explorat 0.023 15% 20,067 $6,682,116 AVW Avira Resources Ltd 0.008 14% 108,829 $1,610,000 Ovanti (ASX:OVT) has named Zip Co (ASX:ZIP) exec Peter Maher as CEO of its US BNPL, payments and embedded finance arm. Maher, who helped grow Zip's American business under co-founder Larry Diamond, will join OVT on July 14 after serving out his notice. Ovanti picked him after a global search, banking on his track record in big merchant deals, AI-led affordability tools and launching BNPL products that ditch credit scores for real-time income data. OVT reckons that's the key to cracking the US market, and Maher's the one to do it. Reedy Lagoon (ASX:RLC) has lined up a handful of promising drill targets at its Burracoppin gold project in WA's Wheatbelt, sitting between Perth and Kalgoorlie. Using magnetic data and over 3,000 soil samples, it's pinpointed gold anomalies across four main prospects – Lady Janet, Windmills, Shear Luck and Zebra. The land's flat and mostly covered in crops or sheep, with little rock showing, so the company's been relying on geophysics and soil to guide the way. First-pass drilling is now on the cards to see what's hiding in the bedrock. Li-S Energy (ASX:LIS) has signed a deal with a major defence tech company to test its lithium-sulfur batteries for global military use. The partner, which supplies advanced gear to defence forces in the US, Europe and Australia, will put LIS cells through their paces for performance and safety. The two plan to explore how Li-S tech could be integrated into military systems. And, Dateline Resources (ASX:DTR) boss Stephen Baghdadi tipped in $1.06 million by exercising his options on the stock, lifting his stake to almost 13%. Shares were up 5%. ASX SMALL CAP LOSERS Here are the worst performing ASX small cap stocks for June 25 : Code Name Price % Change Volume Market Cap AUK Aumake Limited 0.002 -33% 16,655 $9,070,076 JAY Jayride Group 0.001 -33% 10 $2,141,834 RAN Range International 0.001 -33% 2,836,500 $1,408,935 HLX Helix Resources 0.002 -25% 2,525,000 $6,728,387 PV1 Provaris Energy Ltd 0.014 -21% 1,849,161 $11,866,022 OLH Oldfields Holdings 0.020 -20% 40,500 $5,326,478 EAT Entertainment 0.004 -20% 54,200 $6,543,930 FIN FIN Resources Ltd 0.004 -20% 199,998 $3,474,442 KPO Kalina Power Limited 0.004 -20% 6,554,734 $14,664,978 MEL Metgasco Ltd 0.002 -20% 179,775 $4,581,467 EWC Energy World Corpor. 0.021 -19% 4,422,520 $80,051,952 14D 1414 Degrees Limited 0.014 -18% 472,948 $4,892,243 VRL Verity Resources 0.019 -17% 2,383,681 $6,426,740 AUR Auris Minerals Ltd 0.005 -17% 84,413 $2,859,756 JAV Javelin Minerals Ltd 0.003 -17% 147,000 $18,378,447 LML Lincoln Minerals 0.005 -17% 5,371,284 $12,615,418 X2M X2M Connect Limited 0.022 -15% 2,228,843 $10,092,728 LMG Latrobe Magnesium 0.009 -15% 2,076,872 $26,265,900 ODE Odessa Minerals Ltd 0.006 -14% 1,540,131 $11,196,728 RDS Redstone Resources 0.003 -14% 720,000 $3,619,936 MPR Mpower Group Limited 0.007 -13% 133,000 $2,749,626 IRX Inhalerx Limited 0.042 -13% 100,000 $10,245,515 ZNC Zenith Minerals Ltd 0.036 -12% 23,448 $16,883,748 IVX Invion Ltd 0.110 -12% 79,218 $10,591,082 LAT Latitude 66 Limited 0.022 -12% 273,154 $3,585,018 IN CASE YOU MISSED IT A recent research report has given Belararox (ASX:BRX) a target share price of 44 cents and market cap of $60m based on its copper projects. Besra Gold (ASX:BEZ) continues to de-risk key workstreams required to complete the bankable feasibility study for its Jugan project within the Bau gold field in Sarawak, Malaysia. ADX Energy's (ASX:ADX) focus on testing shallow gas prospects in Austria has led Auctus Advisors to maintain its 30c price target. Core Energy Minerals (ASX:CR3) will drill an initial 50 aircore holes at its Cummins uranium project in South Australia, with scope to expand to up to 120 holes under approved permits. Legacy Minerals (ASX:LGM) has welcomed the start of drilling at the Glenlogan project joint venture with S2 Resources on the hunt for a copper-gold porphyry target. Astute Metals' (ASX:ASE) drilling has returned consistently high-grade lithium intersections at its Red Mountain project in Nevada. Brightstar Resources (ASX:BTR) has signed a MoU with Paddington Gold to purchase ore from its Menzies gold project in WA. LAST ORDERS Pursuit Minerals (ASX:PUR) is $300,000 richer after finalising the sale of its Commando and Warrior projects in WA to Kurnalpi Gold Pty Ltd, a privately held company. PUR has now divested 100% of its legal and beneficial interests in the tenements. Norfolk Metals (ASX:NFL) is anticipating a busy second half of 2025 at the Carmen copper project, having established an operations camp to house its ground teams just an hour away from the site. NFL has ambitions to prove-up a shallow copper oxide resource of large enough size to develop a low-cost, high-margin, value-accretive heap leaching operation producing copper cathode at the mine gate. Trigg Minerals (ASX:TMG) has welcomed US executive Ben Harris as US Defence and Armaments Advisor to support Trigg's strategy to become a secure, domestic supplier of the critical mineral antimony. With more than 35 years' experience in the US defence and government sectors, Harris will support TMG's efforts to align the Antimony Canyon project in Utah with US national security and federal procurement priorities. At Stockhead, we tell it like it is. While Pursuit Minerals, Norfolk Metals and Trigg Minerals are Stockhead advertisers, they did not sponsor this article.

2026 Toyota Corolla Cross price, spec details leaked
2026 Toyota Corolla Cross price, spec details leaked

The Advertiser

timean hour ago

  • The Advertiser

2026 Toyota Corolla Cross price, spec details leaked

Key details of the updated 2026 Toyota Corolla Cross lineup, including pricing, has been leaked online. A dealer bulletin shared on the Toyota Corolla Cross Owners Australia group on Facebook reveals the entire lineup will receive a $960 price hike, while also detailing some of the spec changes coming to the small crossover SUV. Toyota has previously confirmed a local launch for the upgraded small SUV in the second half of 2025. We've contacted the company for an update. Per the bulletin, the Corolla Cross will arrive at dealerships in late July in both GX and Atmos trims, with the GXL and new GR-S trim (pictured below) arriving in early October. Hundreds of new car deals are available through CarExpert right now. Get the experts on your side and score a great deal. Browse now. The bulletin mentions "production delays due to pending certification" for the GXL and GR-S, which were originally set to arrive alongside the rest of the range. The updated lineup will open at $37,440 before on-road costs for the base front-wheel drive GX, and top out at $50,990 before on-roads for both the all-wheel drive Atmos and GR-S. All variants get HF01234YF refrigerant for their air-conditioning systems and an Acoustic Vehicle Alerting System (AVAS) to alert passersby to the hybrid SUV's presence. The front and rear Parking Support Brake function, which applies the brakes if it detects an object or vehicle and which was previously exclusive to the Atmos, is being rolled out to the GX and GXL. The GXL also picks up the following features from the Atmos: The Atmos gains ventilated front seats. There's also updated centre console trim for the GX, GXL and Atmos. The new GR-S (or GR Sport) variant revealed in May features unique front and rear bumpers, as well as lower sports suspension, retuned steering, and unique 19-inch alloy wheels. Ever since petrol-powered variants were dropped locally in 2024, all Australian-market Corolla Cross vehicles come with a 2.0-litre four-cylinder hybrid powertrain delivering 146kW of total system power. The wider range receives refreshed exterior styling including new LED headlight internals for the GXL and Atmos. Toyota may be the best-selling car brand in Australia by a country mile, but the Corolla Cross was only the seventh best-selling vehicle in its segment last year, behind the MG ZS, Hyundai Kona, GWM Haval Jolion, Mazda CX-30, Mitsubishi ASX and Subaru Crosstrek. Here's the pricing as it appears in the dealer bulletin: MORE: Everything Toyota Corolla Cross Content originally sourced from: Key details of the updated 2026 Toyota Corolla Cross lineup, including pricing, has been leaked online. A dealer bulletin shared on the Toyota Corolla Cross Owners Australia group on Facebook reveals the entire lineup will receive a $960 price hike, while also detailing some of the spec changes coming to the small crossover SUV. Toyota has previously confirmed a local launch for the upgraded small SUV in the second half of 2025. We've contacted the company for an update. Per the bulletin, the Corolla Cross will arrive at dealerships in late July in both GX and Atmos trims, with the GXL and new GR-S trim (pictured below) arriving in early October. Hundreds of new car deals are available through CarExpert right now. Get the experts on your side and score a great deal. Browse now. The bulletin mentions "production delays due to pending certification" for the GXL and GR-S, which were originally set to arrive alongside the rest of the range. The updated lineup will open at $37,440 before on-road costs for the base front-wheel drive GX, and top out at $50,990 before on-roads for both the all-wheel drive Atmos and GR-S. All variants get HF01234YF refrigerant for their air-conditioning systems and an Acoustic Vehicle Alerting System (AVAS) to alert passersby to the hybrid SUV's presence. The front and rear Parking Support Brake function, which applies the brakes if it detects an object or vehicle and which was previously exclusive to the Atmos, is being rolled out to the GX and GXL. The GXL also picks up the following features from the Atmos: The Atmos gains ventilated front seats. There's also updated centre console trim for the GX, GXL and Atmos. The new GR-S (or GR Sport) variant revealed in May features unique front and rear bumpers, as well as lower sports suspension, retuned steering, and unique 19-inch alloy wheels. Ever since petrol-powered variants were dropped locally in 2024, all Australian-market Corolla Cross vehicles come with a 2.0-litre four-cylinder hybrid powertrain delivering 146kW of total system power. The wider range receives refreshed exterior styling including new LED headlight internals for the GXL and Atmos. Toyota may be the best-selling car brand in Australia by a country mile, but the Corolla Cross was only the seventh best-selling vehicle in its segment last year, behind the MG ZS, Hyundai Kona, GWM Haval Jolion, Mazda CX-30, Mitsubishi ASX and Subaru Crosstrek. Here's the pricing as it appears in the dealer bulletin: MORE: Everything Toyota Corolla Cross Content originally sourced from: Key details of the updated 2026 Toyota Corolla Cross lineup, including pricing, has been leaked online. A dealer bulletin shared on the Toyota Corolla Cross Owners Australia group on Facebook reveals the entire lineup will receive a $960 price hike, while also detailing some of the spec changes coming to the small crossover SUV. Toyota has previously confirmed a local launch for the upgraded small SUV in the second half of 2025. We've contacted the company for an update. Per the bulletin, the Corolla Cross will arrive at dealerships in late July in both GX and Atmos trims, with the GXL and new GR-S trim (pictured below) arriving in early October. Hundreds of new car deals are available through CarExpert right now. Get the experts on your side and score a great deal. Browse now. The bulletin mentions "production delays due to pending certification" for the GXL and GR-S, which were originally set to arrive alongside the rest of the range. The updated lineup will open at $37,440 before on-road costs for the base front-wheel drive GX, and top out at $50,990 before on-roads for both the all-wheel drive Atmos and GR-S. All variants get HF01234YF refrigerant for their air-conditioning systems and an Acoustic Vehicle Alerting System (AVAS) to alert passersby to the hybrid SUV's presence. The front and rear Parking Support Brake function, which applies the brakes if it detects an object or vehicle and which was previously exclusive to the Atmos, is being rolled out to the GX and GXL. The GXL also picks up the following features from the Atmos: The Atmos gains ventilated front seats. There's also updated centre console trim for the GX, GXL and Atmos. The new GR-S (or GR Sport) variant revealed in May features unique front and rear bumpers, as well as lower sports suspension, retuned steering, and unique 19-inch alloy wheels. Ever since petrol-powered variants were dropped locally in 2024, all Australian-market Corolla Cross vehicles come with a 2.0-litre four-cylinder hybrid powertrain delivering 146kW of total system power. The wider range receives refreshed exterior styling including new LED headlight internals for the GXL and Atmos. Toyota may be the best-selling car brand in Australia by a country mile, but the Corolla Cross was only the seventh best-selling vehicle in its segment last year, behind the MG ZS, Hyundai Kona, GWM Haval Jolion, Mazda CX-30, Mitsubishi ASX and Subaru Crosstrek. Here's the pricing as it appears in the dealer bulletin: MORE: Everything Toyota Corolla Cross Content originally sourced from: Key details of the updated 2026 Toyota Corolla Cross lineup, including pricing, has been leaked online. A dealer bulletin shared on the Toyota Corolla Cross Owners Australia group on Facebook reveals the entire lineup will receive a $960 price hike, while also detailing some of the spec changes coming to the small crossover SUV. Toyota has previously confirmed a local launch for the upgraded small SUV in the second half of 2025. We've contacted the company for an update. Per the bulletin, the Corolla Cross will arrive at dealerships in late July in both GX and Atmos trims, with the GXL and new GR-S trim (pictured below) arriving in early October. Hundreds of new car deals are available through CarExpert right now. Get the experts on your side and score a great deal. Browse now. The bulletin mentions "production delays due to pending certification" for the GXL and GR-S, which were originally set to arrive alongside the rest of the range. The updated lineup will open at $37,440 before on-road costs for the base front-wheel drive GX, and top out at $50,990 before on-roads for both the all-wheel drive Atmos and GR-S. All variants get HF01234YF refrigerant for their air-conditioning systems and an Acoustic Vehicle Alerting System (AVAS) to alert passersby to the hybrid SUV's presence. The front and rear Parking Support Brake function, which applies the brakes if it detects an object or vehicle and which was previously exclusive to the Atmos, is being rolled out to the GX and GXL. The GXL also picks up the following features from the Atmos: The Atmos gains ventilated front seats. There's also updated centre console trim for the GX, GXL and Atmos. The new GR-S (or GR Sport) variant revealed in May features unique front and rear bumpers, as well as lower sports suspension, retuned steering, and unique 19-inch alloy wheels. Ever since petrol-powered variants were dropped locally in 2024, all Australian-market Corolla Cross vehicles come with a 2.0-litre four-cylinder hybrid powertrain delivering 146kW of total system power. The wider range receives refreshed exterior styling including new LED headlight internals for the GXL and Atmos. Toyota may be the best-selling car brand in Australia by a country mile, but the Corolla Cross was only the seventh best-selling vehicle in its segment last year, behind the MG ZS, Hyundai Kona, GWM Haval Jolion, Mazda CX-30, Mitsubishi ASX and Subaru Crosstrek. Here's the pricing as it appears in the dealer bulletin: MORE: Everything Toyota Corolla Cross Content originally sourced from:

Health Check: UBS turns ultra-bullish on Aussie healthcare leaders
Health Check: UBS turns ultra-bullish on Aussie healthcare leaders

News.com.au

timean hour ago

  • News.com.au

Health Check: UBS turns ultra-bullish on Aussie healthcare leaders

UBS reckons healthcare will fare better than any other ASX sector Bell Potter says Monash IVF has fertile recovery prospects Telix wins FDA usage expansion for prostate cancer imaging Financial giant UBS has declared that enough is enough with lagging healthcare valuations – and now believes it will be the best performer of any ASX sector. In bestowing 'pet sector' status, the firm says that healthcare stocks are the cheapest they have been in 10 years. This follows three years of remorseless earnings per share (EPS) downgrades. The firm opines healthcare now offers the best EPS growth of all ASX sectors, with an expected increment of almost 20% in the 2025-26 year. The S&P/ASX 200 healthcare index has fallen 5% over the past 12 months and is down 7% year to date. In contrast, the broader ASX200 index looks to be finishing the year around 9% higher. 'Investor sentiment towards the healthcare sector has broadly cooled over the last year, with some marked deterioration seen across many stocks,' UBS says. ' Cochlear (ASX:COH) in particular has seen investor apathy build over the last year, which represents a significant change of views versus .' The firm has upgraded Cochlear to a 'buy' for the first time since 2011. 'Challenging market conditions' Meanwhile, Bell Potter notes that 'challenging market conditions' have mostly persisted for small and mid-cap healthcare stocks. Of the 35 stocks the firm covers, only nine are trading at a premium to their December-end values. 'The macro factors driving this broader performance include the uncertainty arising from leadership changes at the US Food and Drug Administration (FDA) and proposals to lower prescription drug price in the US,' the firm says. 'Consequently, institutional investors have largely adopted a wait-and-see approach.' However, Bell Potter expects new drug approvals and earnings growth 'to lead to a wave of new capital flowing into the sector'. Oh baby! That's an interesting call Bell Potter's three favourite healthcare stocks include the troubled Monash IVF Group (ASX:MVF), if only because the share price reaction to the company's embryo-woes looks excessive. In the broker's half-year run-down of best buys across all sectors, the firm's other two healthcare picks are Telix – that name again – and Neuren Pharmaceuticals (ASX:NEU). Monash IVF's two reported embryo transfer errors resulted in the June 12 resignation of CEO Michael Knaap. Prominent silk Fiona McLeod is carrying out an independent probe into the snafus. Meanwhile, Monash IVF shares have halved since January. Bell Potter says Monash IVF trades on a multiple of six times. This compares with 12.5 times for nearest rival Virtus Health in 2022, when it was taken over by BGH Capital and delisted. 'The depressed share price may also invite a bid for the company adding corporate appeal to a deep value investment thesis.' The firm reckons Monash IVF is worth $1.15 a share, more than twice its current valuation. On safe ground With Telix, Bell Potter says revenues from its lead prostate imaging product Illucix should continue to grow as it wins US market share. The FDA recently approved another prostate imaging agent, Gozellix, and should green light the kidney cancer imaging product Zircaix in the September quarter. Neuren is making hay from US sales of its Rett syndrome therapy Daybue, via partner Acadia. But the firm believes the bigger value driver is Neuren's separate compound NNZ-2591. This is for the rare 'orphan' diseases Phelan-McDermid, Angelman, Pitt Hopkins and Prader-Willi syndromes. NNZ-2591 is thought to be more effective and less toxic than Daybue – and the market could be bigger. Neuren reported positive phase II trial results for Phelan-McDermid and expects to kick off a phase III study within months. With $340 million of cash, Neuren has oodles of dosh to fund the 160-patient trial. In fact, the company is undertaking a share buyback to soak up stock at discounted levels. Bell Potter also rates Mesoblast Mesoblast (ASX:MSB), Clarity Pharmaceuticals (ASX:CU6), Immutep (ASX:IMM) and EBR Systems (ASX:EBR) as speculative buys. Telix in FDA win Back to Telix – yet again – the FDA has approved a label extension for Illucix. This will enable doctors to patients for radioligand (targeted radiation) therapy earlier in the piece, before they progress to chemotherapy. Telix estimates clinical use of Illuccix will increase by at least 20,000 scans annually. The label expansion piggybacks the FDA's recent approval of an expanded indication for Novartis's Pluvicto radioligand therapy. The firm says Telix's imaging has become a standard of care in prostate cancer detection and management. The FDA also recently approved Telix's Gozellix, another prostate cancer imaging agent. Cleo pops down to the (bio) bank The US National Cancer Institute has granted ovarian cancer diagnostics developer Cleo Diagnostics (ASX:COV) access to a US cache of blood samples. Collected from 155,000 cancer patients over the last decade, the repository is called the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) biobank. Cleo says PLCO is a a gold-standard resource, having derived from one of the 'largest and most influential US longitudinal cancer studies'. Cleo will use the data to strengthen its FDA marketing submission for a pre-surgical test and expects to complete the supporting trials by the end of the year. Earlier, Cleo entered a compact with University College London to access a capacious ovarian cancer biobank. 'Together, these biobanks form a comprehensive, internationally representative ... population that Cleo will use to enhance its clinical evidence and substantially derisk key regulatory milestones,' Cleo CEO Richard Allman says. Cleo's two trials pertain to pre-surgical identification and screening of an asymptomatic population. Earlier studies showed Cleo's tool confirmed or ruled out tumours 95% of the time, thus outperforming standard-of-care assays. Capital raising corner At the smaller end of the sector, companies are raising enough to keep the lights on – and perhaps a little more. The maker of asthma adherence devices that wrap around 'puffers', Adherium (ASX:ADR) plans to raise $4 million at half a cent apiece. This is by way of an insto and retail offer, partly underwritten and struck at half a cent. Investors also get one option for every share issued, as well as a 'piggyback' bonus option. An existing holder Phillip Thematic Fund has its hands up for $800,000, while Phillip Asset Management and Trudell Medical are good for $1 million of underwriting. Heart device play Cardiex (ASX:CDX) has raised about $4.1 million in a rights offer, having gathered $2.4 million in a placement. Both were done at four cents a share. TALi Digital (ASX:TD1) is seeking $1.48 million in a right issue, having mustered $800,000 in a private placement. Both were struck at one-tenth of a cent per share. Tali is developing tools that test kids for conditions including autism and attention deficit hyperactivity disorder. This month Tali acquired You Can Do It! Education, 'a social-emotional learning program aimed at improving the social, emotional, and academic outcomes of young people.'

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store